Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy

Table 1 Blocking of maternal transmission in HBsAg and HBeAg double-positive mothers[19]

	n	HBsAg(+)			HBV-DNA(+)	Blockingrate
		T0	T6	T12
Lamivudine treatment	12	3	0	0	0	100.00
Vaccine 30-30-10 μg	81		21	21	21	74.07
Vaccine 30-20-10 μg	37		13	13	13	64.87
Natural transmission	10		10	10	10	0.00

Table 2 Complications of pregnancy in different groups [19]

	Abortion(%)	Preterm(%)	Neonatalasphyxia (%)	Fetaldeath (%)	Congenitalanomaly (%)
Lamivudin	0/38	0/38	0/38	0/38	0/38
Control	16.67	43.02	15.62	4.49	10
	(1/6)	(37/86)	(14/89)	(4/89)	(1/10)

Table 3 Control of hepatitis activity[22]

	n	Activehepatitis (%)
Lamivudine treatment during pregnancy	38	0 (0.00)
Stop lamivudine while pregnant	2	2 (100.00)
Stop lamivudine	41	7 (17.07)